Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 6/20 | 0.66 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SGK1 | O00141 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 2/20 | 0.32 |
| ▸ | STK25 | O00506 | 2/20 | 0.32 |
| ▸ | CIT | O14578 | 2/20 | 0.32 |
| ▸ | CASK | O14936 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.32 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.32 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ULK1 | O75385 | 2/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.32 |
| ▸ | STK16 | O75716 | 2/20 | 0.32 |
| ▸ | PAK4 | O96013 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285223 | 0.86 | SF3B3 (0.87) | SF3B3ACKR3P2RY2ADORA1SGK1 | |
| SCHEMBL1505072 | 0.80 | SF3B3 (0.51) | SF3B3 | |
| SCHEMBL905687 | 0.76 | SF3B3 (0.45) | SF3B3 | |
| SCHEMBL1504944 | 0.76 | SF3B3 (0.46) | SF3B3 | |
| SCHEMBL1504930 | 0.74 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL1505055 | 0.73 | SF3B3 (0.42) | SF3B3 | |
| SCHEMBL1267678 | 0.68 | SF3B3 (0.45) | SF3B3 | |
| SCHEMBL1505220 | 0.66 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL3869393 | 0.66 | SF3B3 (0.40) | SF3B3 | |
| SCHEMBL3876413 | 0.66 | SF3B3 (0.44) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | SF3B3, SF3B2, SF3B1 | SF3B3 1/4885ACKR3 1810/4885P2RY2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.